Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 21, 2007. The report discloses the notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) regarding awards granted under the company's Performance Share Plan and Share Option Plan on February 20, 2007.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses exclusively on executive compensation structures and share pricing at the time of grant.
- Share Price at Grant: GBP 14.88 per Ordinary Share; US$ 58.00 per American Depository Share (ADS).
- ADS Conversion: One ADS equals two Ordinary Shares.
- Grant Date: February 20, 2007.
- Normal Vesting Date: February 20, 2010.
Material Changes and Plan Details
The filing details two distinct compensation plans with specific performance conditions for the 2007-2009 measurement period:
Performance Share Plan
- Condition: Vesting is contingent on Total Shareholder Return (TSR) relative to a comparator group of 14 pharmaceutical companies (including Abbott, AstraZeneca, Pfizer, and Roche).
- Vesting Thresholds: No awards vest if GSK ranks below the median. Vesting increases on a sliding scale to 100% if GSK ranks 1st or 2nd.
- Recipients: Awards were granted to Executive Directors (e.g., J.S. Heslop, J.P. Garnier) and other PDMRs in both Ordinary Shares and ADSs.
Share Option Plan
- Condition: Vesting depends on the compound annual increase in Earnings Per Share (EPS) compared to the Retail Price Index (RPI) plus a 3% hurdle.
- Vesting Thresholds: No options vest unless EPS growth exceeds RPI by 3% p.a. 50% vest at the 3% hurdle, increasing to 100% if EPS growth exceeds RPI by 6% p.a. or more.
- Subscription Price: Set at the market price on the grant date (GBP 14.88 / US$ 58.00).
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on business outlook, or general risk factors. The primary contingency noted is that all awards are subject to performance conditions; if conditions are not met, awards will not vest or options will lapse. Dividends accrue on performance shares during the vesting period and vest proportionally with the shares.
Investor Verification Checklist
- Verify the specific TSR ranking of GSK against the 14 comparator companies over the 2007-2009 period to determine actual vesting of performance shares.
- Confirm the compound annual EPS growth rate versus RPI for the 2007-2009 period to calculate the vesting percentage of share options.
- Review the full list of comparator companies to ensure accurate peer group analysis.
- Check subsequent filings for any modifications to the plans or early termination of awards.